Effects of Achieving Sustained Virological Response on Outcomes Following Hepatectomy for Hepatitis C-Associated Hepatocellular Carcinoma: A Retrospective Analysis - Scorecard - MDSpire
Advertisement
Effects of Achieving Sustained Virological Response on Outcomes Following Hepatectomy for Hepatitis C-Associated Hepatocellular Carcinoma: A Retrospective Analysis
Clinical Scorecard: Effects of Achieving Sustained Virological Response on Outcomes Following Hepatectomy for Hepatitis C-Associated Hepatocellular Carcinoma: A Retrospective Analysis
At a Glance
Category
Detail
Condition
Hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC)
Key Mechanisms
Direct-acting antiviral (DAA) therapy leading to sustained virological response (SVR) defined as undetectable HCV RNA 12 weeks post-treatment
Target Population
Patients with pathologically confirmed HCV-related HCC undergoing curative hepatectomy
Care Setting
Tertiary cancer hospital surgical and hepatology departments
Key Highlights
Hepatectomy is the most effective treatment for HCC but prognosis is poor due to late-stage diagnosis.
DAA-induced SVR significantly reduces incidence of de novo HCC, all-cause mortality, and liver-related mortality in chronic HCV infection.
The impact of DAA therapy on post-hepatectomy tumor recurrence, metastasis risk, and survival remains inconclusive.
Guideline-Based Recommendations
Diagnosis
Confirm HCV infection by positive serum HCV RNA detection.
Diagnose HCC pathologically post-hepatectomy.
Management
Perform curative hepatectomy as primary treatment for HCV-related HCC.
Administer perioperative DAA therapy to achieve SVR, typically starting one week before surgery.
Monitoring & Follow-up
Assess SVR by measuring serum HCV RNA 12 weeks after completion of antiviral therapy.
Monitor for tumor recurrence and survival outcomes post-hepatectomy.
Risks
Potential immortal time bias in retrospective studies necessitates landmark analysis to validate survival benefits.
Uncertainty remains regarding DAA therapy's effect on post-operative tumor recurrence and metastasis.
Patient & Prescribing Data
75 patients with HCV-related HCC undergoing curative hepatectomy; 49 received DAA therapy achieving SVR, 26 untreated.
Perioperative DAA therapy initiated around hepatectomy can suppress viral replication early and may improve long-term prognosis.
Clinical Best Practices
Screen HCV RNA status preoperatively to identify candidates for DAA therapy.
Initiate DAA therapy perioperatively to maximize viral suppression and potential survival benefit.
Exclude patients with incomplete data or perioperative mortality to ensure data integrity in retrospective analyses.
Use landmark analysis to address immortal time bias in survival studies involving antiviral treatment.
